Menu
Recruiting NCT07402616

Ex Vivo Cutaneous SCC

No phase Interventional Cutaneous Squamous Cell Carcinoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: ex vivo 3D ultrasonography.
Who it may be relevant to
Registry conditions: Cutaneous Squamous Cell Carcinoma. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Denmark
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Feasibility of 3D ex Vivo Ultrasonography for Post-operative Evaluation of Tumor Margins in Cutaneous Squamous Cell Carcinoma

Overview

This is a prospective study including patients ( ≥ 18 years) referred for surgical treatment of primary cutaneous squamous cell carcinoma at the Department of Plastic Surgery, Rigshospitalet. After written and informed consent, patients will undergo standard surgical excision, followed by ex vivo 3D ultrasonography of the specimen using a 3Sonic device connected to a high-frequency ultrasound machine. This will create 3D ultrasound tomographic scans which will be interpreted by one investigator blinded to histopathology. The investigated outcomes will primarily be the deep margin distance. This will be compared to histopathology, where a pathologist - blinded to the ultrasonography results - will slice the entire specimen parallel to the ultrasound images. A third investigator will then match the histopathology images to the ultrasound images for correlation of the measured deep margins.

Interventions

  • Diagnostic test ex vivo 3D ultrasonography
    Surgical specimens scanned with 3D ultrasonography

Primary outcome measures

  • Deep margin distance [Time frame: Within 10-14 days from enrollment]
Secondary outcome measures (2)
  • Depth of invasion [Time frame: Within 10-14 days from enrollment]
  • Tumor size in 3 dimensions measured in mm with ultrasound and histopathology [Time frame: Within 10-14 days from enrollment]

Eligibility criteria

Inclusion criteria

  • Adults with primary cutaneous squamous cell carcinoma.

Exclusion criteria

  • Carcinomas located on the eyelids, vulva, penis, or perianal.
  • Tumors with an anticipated excision larger than 60mm.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Diagnostic

Study locations

Denmark · 1 center
  • Rigshospitalet — Copenhagen

Identifiers

NCT: NCT07402616 · Ex vivo cutaneous SCC

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗